The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since 
INTRODUCTION
Glaucoma comprises a group of disorders characterized by a distinctive optic neuropathy that leads to progressive asymptomatic visual field loss. It is thought that loss of vision in glaucoma is associated with damage to the optic nerve and retina that results in irreversible retinal ganglion cell damage. Glaucoma is currently the leading cause of irreversible blindness worldwide. It has been estimated that the total number of patients with glaucoma will be close to 80 million by 2020 [1] .
Because glaucomatous neuropathy is usually associated with elevation of intraocular pressure (IOP), the main objective of all available treatment options comprises a meaningful IOP reduction to a predetermined level, which is commensurate with either stability or delayed progression of visual loss [2] . When medical and laser therapies fail to control IOP, glaucoma filtration surgery (GFS) is usually necessary. GFS techniques lower the IOP by establishing an surgical outflow channel through which the aqueous humor drains continuously from the anterior chamber to the sub-Tenon and subconjunctival space [3] .
Nevertheless, the long-term success of GFS is often compromised by the relentless wound-healing process ultimately blocking the surgically created outflow pathway at the conjunctival and episcleral plane. Diverse molecular and cellular processes such as collagen deposition, angiogenesis, and the activation and proliferation of fibroblasts are implicated in the healing process which eventually obstructs aqueous outflow [4] . As a result, glaucoma surgery often fails to adequately control IOP and the patient's visual decline continues [5, 6] . The success of GFS has improved considerably following the intraoperative and postoperative application of antimetabolites such as 5-fluorouracil and mitomycin C.
However, it should be emphasized that the mechanism by which these molecules prevent healing is nonspecific and can lead to excessive collateral tissue damage. Excessive prevention of wound healing observed in antimetabolite-augmented GFS is associated with complications such as postoperative hypotony, infections, corneal toxicity, and a thin-walled avascular bleb, which is prone to leakage [7] [8] [9] . Consequently, approaches to modulate the wound-healing response with medications that have an improved safety profile are under investigation.
Angiogenesis is a key element of the wound-healing process and is essential for the ultimate formation of granulation tissue.
Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis known to promote the migration of inflammatory cells and fibroblasts as well as having a direct effect upon the activity of fibroblasts [10] . On the basis of this hypothesis, the adjunctive use of VEGF inhibitors has been recently tried in GFS [11] [12] [13] [14] . It has been postulated that the use of these selective wound modulators may enhance surgical efficacy and, at the same time, offer a more favorable safety profile.
As a result of their mechanism of action, VEGF 165 (45 kDa) is the predominant isoform and the key agent in neovascularization [27] .
The function of these molecules is primarily mediated by binding and activating two transmembrane tyrosine kinase receptors, VEGFR-1 and VEGFR-2 [28, 29] . Additionally, VEGF binds to isoform-specific VEGF receptors (neuropilins) expressed in endothelial and non-endothelial cells [30, 31] 
Anti-VEGF Therapy in Neovascular Glaucoma
In the setting of NVG, a number of studies have investigated the use of anti-VEGF antibodies, such as BVZ, RBZ, and AFB by topical, intracameral, or intravitreal administration (Table 1 ). In a pilot study published by Waisbourd et al. [59] the efficacy of topically applied BVZ for the treatment of NVG was evaluated. Eight patients were treated with topical BVZ (25 mg/mL) four times daily for 2 weeks. The authors observed a mean IOP reduction of 6.1 mmHg and noted that three patients had clinical regression of iris neovascularization [59] . The intracameral administration of BVZ reduced the number of patients requiring surgical treatment of NVG, whereas some other patients became candidates for filtration surgery [60] . In a separate study, a decreased leakage from new iris vessels was observed 1 day after an intracameral injection of BVZ [61] .
In a 12-month prospective clinical series published by Lüke et al. [62] , 10 cases with NVG received intraocular injections of RBV (0.5 mg/0.05 mL). According to the authors, RBV appeared to be beneficial owing to its anti-angiogenic properties and its ability to prevent or halt anterior chamber angle occlusion [62] . In the same context, Grover et al. [63] reported a considerable reduction in aqueous humor VEGF concentrations following an intracameral injection of BVZ. Furthermore, in a randomized trial of 26 patients treated with intravitreal BVZ, a significant IOP reduction was noted as well as a significant regression of neovascularization compared to sham injections [64] . However, the use of intravitreal BVZ in a later study did not significantly reduce the frequency of hyphema and fibrin formation in the anterior chamber 1 day after surgery and a single injection of the anti-VEGF was insufficient to completely eliminate iris neovascularization [65] .
Similarly, in a retrospective review recurrent anterior segment neovascularization was seen after a single intravitreal injection of BVZ [66] .
It is worth noting that these authors reported that trabeculectomy provided a protective effect against the recurrence of anterior segment neovascularization [66] . In a more recent study, four patients with newly diagnosed stage 1 or 2 NVG received an intravitreal injection of AFB (2 mg) at the time of diagnosis and then additional injections at 4 weeks, 8 weeks, and at 8-week intervals for 52 weeks [25] . Results showed that iris and angle neovascularization regressed and IOP was either stable or significantly reduced in all patients at the end of the study [25] .
Wound Modulation in Glaucoma Filtration Surgery
The wound-healing process consists of four continuous, overlapping, and well-orchestrated phases: hemostasis, inflammation, proliferation, and tissue remodeling. During the healing process, several events take place in a synchronized manner: (a) rapid hemostasis, (b) inflammation, (c) mesenchymal cell differentiation, proliferation, and migration to the wound site, (d) controlled angiogenesis, (e) regrowth of epithelial tissue over the wound surface, and (f) synthesis, cross-linking, and alignment of collagen to provide strength to the healing tissue [67] . Contrary to many other surgical procedures, the success of GFS relies on inhibition of the wound-healing process. Since VEGF plays a key role in both physiological and pathological angiogenesis, the use of VEGF inhibitors as selective wound modulators with a more favorable safety profile has been intensively studied over the past few years.
Role of VEGF in Wound Modulation
VEGF is produced by different cell types including endothelial cells [69] , macrophages [70] , fibroblasts [71] , platelets [72] , neutrophils [73] , and smooth muscle cells [74] . All cell types participate in the wound-healing process so VEGF stimulates multiple components of the wound-healing cascade, such as angiogenesis, epithelization, and collagen deposition [75] . Among the five existing isoforms of VEGF, the predominant VEGF 165 
Anti-VEGF Therapy in GFS
A number of studies have investigated the topical, intracameral, subconjunctival, and intravitreal administration of anti-VEGF antibodies such as BVZ and RBZ in the context of GFS (Tables 1, 2) . In an experimental model of GFS in rabbits, the bleb area could be increased if BVZ was applied into the anterior chamber (5 mg) and the subconjunctival space (2.5 mg) during trabeculectomy. However, the authors did not detect significant differences in the IOP of these animals between treated and control eyes 29 days after surgery [77] . Similar results were obtained in a study in which subconjunctival injection of 1.25 mg BVZ, 5-FU, or balanced salt solution (BSS; control) was performed in rabbits (n = 42) that underwent trabeculectomy [78] . These authors did report longer bleb survival in the BVZ group in comparison to the 5-FU and control groups, but the mean IOP across all groups was similar [78] . In a different study, subconjunctival injections of BVZ (1.25 mg) generated bigger and higher blebs and lower mean IOP in a rabbit model of filtration surgery, in comparison with intravitreal injections of BVZ, 5-FU, or BSS [79] .
The use of anti-VEGF therapy for preventing bleb failure in patients undergoing single-site phacotrabeculectomy for primary open-angle glaucoma or chronic angle-closure glaucoma has been studied in a randomized controlled clinical trial [80] . In this pilot study, 38 patients were divided into three groups treated with conventional MMC application (0.03%), subconjunctival BVZ (1.25 mg/0.05 mL), or soaked sponges of BVZ (1.25 mg/mL). In both BVZ groups, bleb vascularity increased progressively over the 6-month follow-up. The authors concluded that in their small sample of patients, subconjunctival injections of BVZ (but not soaked sponges of BVZ) were equally effective in reducing IOP in comparison to MMC. The authors suggested that larger clinical trials with a similar study design are needed to corroborate these findings [81] . Tai   Table 2 Summary of studies included in the review on the intraoperative and postoperative application of anti-VEGF drugs in glaucoma filtration surgery, by intracameral (IC), subconjunctival (SC), intravitreal (IV) administration, or applied via soaked sponges (SS)
Intraoperative [77] (IC, SC), [79] (SC, IV), [80] (SC, SS), [83] (SC), [84] (SC)
Postoperative [78] (SC), [82] (SC), [85] (SC), [86] (SC), [87] MMC inhibits conjunctival and scleral fibroblast proliferation at the surgical site but may also cause a certain degree of ciliary body toxicity, thus decreasing aqueous humor production [89] .
The route of administration may become an important consideration in the use of anti-VEGF agents. Intravitreal administration was demonstrated to be the most effective in rabbits [90] . However, subconjunctival administrations result in a longer half-life in both the iris/ciliary body and the retina/choroid, in comparison with intravitreal application. This effect can be explained by the storage effect afforded by the scleral tissue matrix. On the other hand, subconjunctival administrations offer direct modulation of the conjunctival wound-healing process. Although more research is needed to determine the optimal dose of BVZ in these settings, subconjunctival injections containing 1.25 or 2.5 mg of drug were most commonly employed [84, 86] .
SAFETY AND TOLERABILITY
As mentioned previously, in order to delay the wound-healing process, antimetabolites such as MMC and 5-FU have been used in trabeculectomy because of their inhibition of fibroblast migration and proliferation that would otherwise lead to scarring over the filtration site [91] . MMC is used intraoperatively more than twice as often as 5-FU [92] and has been shown to significantly reduce IOP and the risk of surgical failure in eyes that have undergone no previous surgery and in eyes at high risk of failure [93] . On the other hand, antimetabolites are associated with complications such as hypotony, cystic avascular bleb, bleb leak, bleb infection, and endophthalmitis [7] [8] [9] . Because of these, there is a need for more targeted and effective anti-scarring interventions. It has been proven that at the filtration site, VEGF could modify fibroblast activity and stimulate collagen cross-linking and contraction, resulting in scar formation [77] . Moreover, higher VEGF levels in Tenon's tissue preoperatively are associated with a worse outcome following trabeculectomy surgery [9] .
When using BVZ in filtration surgery, one should consider that in several of these studies bleb encapsulation is more frequent with BVZ compared to MMC. In addition, it has been suggested that MMC and 5-FU are more effective than BVZ at reducing IOP and achieving a diffuse filtering bleb in primary trabeculectomy [78, 84, 86, 94] . An explanation for this phenomenon involves the direct toxicity that MMC or 5-FU produces over the ciliary epithelium, which might decrease aqueous humor secretion and, subsequently, Consequently, the use of an anti-VEGF drug and specifically BVZ may be a safer option with regard to corneal toxicity [96] [97] [98] . Additionally, subconjunctival injections of MMC may cause limbal stem cell deficiency [99] . In the study carried out by Sengupta et al. [80] , no toxic effects of 1.25 mg of BVZ were seen in the corneal epithelium or endothelium. Moreover, after 6 months of follow-up, subconjunctival injections of BVZ had a slightly better safety profile compared to the application of sponges soaked with MMC or BVZ. In vitro studies have concluded that BVZ is not toxic to human corneal cells, including corneal endothelial cells, at doses often used for the treatment of corneal neovascularization [100] . A pilot study showed that BVZ eyedrops can sufficiently penetrate the corneal stroma and reach the anterior chamber when administered soon after alkali burns. The same study showed that BVZ eyedrops can significantly reduce corneal damage caused by alkalis [101] .
In conclusion, several comparison studies have shown that the safety and efficacy of anti-VEGF therapy are not significantly different from those of current anti-scarring medications. Considering BVZ, it is an effective and safe agent commonly used in patients with retinal diseases and neovascularization of the anterior segment [102] [103] [104] . However, as an adjuvant for trabeculectomy, one should also consider the contraindications for its use, including pregnancy, breast feeding, uncontrolled systemic hypertension, and cerebrovascular accidents or transient ischemic attacks 1 month prior to injection. Moreover, complications such as conjunctival necrosis have been reported following subconjunctival BVZ [80] and intravitreal RBZ [105] injection.
More specific anti-VEGF agents, possibly targeting VEGF 189 , could prove more potent and safer. In addition, agents with longer duration of effect would be necessary for the long-term success of GFS.
A clinical study with a larger cohort and longer follow-up, such as the one described by Bochmann et al. [106] , would confirm and more accurately highlight the role of anti-VEGF agents in glaucoma surgery. Moreover, targeting the wound-healing process with combination therapy using both
anti-angiogenic and anti-fibrotic agents should be further investigated, as the processes of vessel formation and fibrosis occur at different times in the wound-healing cascade.
ADVANTAGES AND POTENTIAL DRAWBACKS
A number of studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these medications can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate advantages over the more established anti-scarring agents commonly used.
On the other hand, the short-acting effect of anti-VEGF agents is an important inconvenience to consider. Histological studies have shown that maximum proliferation of subconjunctival fibroblasts, an important factor in bleb failure, occurs on the third to fifth postoperative day [107, 108] . Since it is known that the half-life of BVZ is 3-4 days, multiple injections of anti-angiogenic agents are needed to overcome this limitation. At the same time, the pharmacokinetics of BVZ after subconjunctival injections requires further study. The use of BVZ in glaucoma is currently off-label, and several issues need to be addressed in this regard, such as the duration of action and the profile of toxicity to the corneal endothelium, lens, and trabecular meshwork. Well-designed, controlled, prospective studies are needed to confirm these results. Until evidence from high-quality studies becomes available, decisions in clinical practice will need to be based on the existing evidence, the physician's experience, and the patient's preferences.
CURRENT AND FUTURE DEVELOPMENTS
The use of anti-VEGF agents in glaucoma filtration surgery and neovascular glaucoma needs to be supported by more evidence.
Several issues have to be addressed such as the duration of action and the toxicity profile on corneal endothelium, lens, and trabecular meshwork. It is also important to precisely characterize the pharmacokinetics of the different antibodies and determine whether these molecules are capable of blocking all VEGF isomorphs at once. Considering BVZ, poor surgical results using a single dose may justify future trials using multiple doses. Notwithstanding cost, additional injections of BVZ in the postoperative period may improve the survival of trabeculectomy to a degree comparable to that observed with MMC. In order to improve the efficacy of BVZ in this context, parameters such as dose, route of administration, and type of formulations will need to be considered in future studies.
The effects of anti-VEGF agents for treating NVG are temporary, generally lasting 4-6 weeks [111] . It is also known that anti-VEGF agents alone may not be sufficient to treat NVG caused by conditions with a prolonged natural history.
Nonetheless, the combination of anti-VEGF and conventional treatments has the potential to be more effective than conventional treatments alone by virtue of a dual mechanism of action. A further advantage might also be that combined treatments with anti-VEGF and conventional treatments may offer a longer duration of action, allowing a longer interval between injections.
There is an increasingly apparent need for the development of novel systems that allow the delivery of anti-VEGF agents alone or in combination with conventional therapies. In this context, it is crucial that these therapeutic tools provide new alternatives with enhanced therapeutic effects and longer dosing intervals, thus allowing the attainment of therapeutic concentrations over an extended period of time. 
